PsiOxus Therapeutics Closes £22M Series B Equity Financing

PsiOxus Therapeutics, Ltd., an Oxford, UK-based development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases, has closed a £22m (approximately $34m) Series B equity financing.

Backers include existing investors Imperial Innovations Group (AIM: IVO, ‘Innovations’) and Invesco Perpetual and new investors SR One and Lundbeckfond Ventures.

The company intends to use the funding to advance the clinical development of ColoAd1, a systemically available oncolytic vaccine, through a series of phase I and phase II clinical trials for the treatment of colorectal and other forms of cancer.

Originally seed funded by Imperial Innovations and the Mercia Fund and led by CEO Dr John Beadle, PsiOxus is also developing treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.



Join the discussion